A Phase 2 Study of Sequential Trametinib and GSK2141795 in Relapsed or Refractory Multiple Myeloma
This is a phase 2 study to see how useful investigational drug trametinib is, with or
without GSK2141795, in patients with patients with multiple myeloma whose cancer as come
back or there are no standard treatments available for treatment of their disease.
Primary Outcome Measures:
Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.
After completion of study treatment, patients are followed up for 4 weeks.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society